Clopidogrel (cas 113665-84-2)☆
-
Add time:08/28/2019 Source:sciencedirect.com
The prodrug clopidogrel hydrochloride is an irreversible inhibitor of platelet aggregation that must be converted by liver enzymes to an active thiol constituent. The activity of the active thiol product is mediated through the irreversible inhibition of purinergic P2Y12 adenosine diphosphate (ADP) receptors on the surface of platelets. Clopidogrel is indicated for the prophylactic treatment of atherosclerosis in those who have suffered a stroke, myocardial infarction, have peripheral arterial disease, or have received a stent. This agent has been compared to many other antiplatelet drugs and has been demonstrated to be comparable to aspirin in its duration of action and efficacy.
We also recommend Trading Suppliers and Manufacturers of Clopidogrel (cas 113665-84-2). Pls Click Website Link as below: cas 113665-84-2 suppliers
Prev:Silver nanoparticles impregnated chitosan layered carbon nanotube as sensor interface for electrochemical detection of Clopidogrel (cas 113665-84-2) in-vitro
Next:Original ArticleCarotid Endarterectomy and Concurrent Clopidogrel (cas 113665-84-2) Use: National Practice Patterns in the United States) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ArticleCarotid Endarterectomy and Concurrent Clopidogrel (cas 113665-84-2) Use: National Practice Patterns in the United States08/29/2019
- Silver nanoparticles impregnated chitosan layered carbon nanotube as sensor interface for electrochemical detection of Clopidogrel (cas 113665-84-2) in-vitro08/27/2019
- Efficacy and safety of Clopidogrel (cas 113665-84-2) only vs. Clopidogrel (cas 113665-84-2) added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis08/26/2019
- Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel (cas 113665-84-2) Response in Patients Subjected to a Percutaneous Neurointervention08/25/2019
- Original¿Cuál es la dosis óptima de Clopidogrel (cas 113665-84-2) en pacientes pediátricos?What is the optimal dose of Clopidogrel (cas 113665-84-2) in pediatric patients?08/24/2019
- Influence of statin treatment on pharmacokinetics and pharmacodynamics of Clopidogrel (cas 113665-84-2) and its metabolites in patients after coronary angiography/angioplasty08/23/2019
- OriginalConsecuencias clínicas y económicas en pacientes que inician tratamiento con Clopidogrel (cas 113665-84-2) de marca vs. genérico: estudio retrospectivo de vida realClinical and economic consequences in patients initiating therapy with Clopidogrel (cas 113665-84-2) brand-name vs. generic: A real-life retrospective study08/22/2019
- Original ArticleWhat is the optimal dose of Clopidogrel (cas 113665-84-2) in paediatric patients?¿Cuál es la dosis óptima de Clopidogrel (cas 113665-84-2) en pacientes pediátricos?☆08/21/2019
-
Health and Chemical more >